208 related articles for article (PubMed ID: 14742984)
21. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group.
Transplantation; 1996 Apr; 61(7):1029-37. PubMed ID: 8623181
[TBL] [Abstract][Full Text] [Related]
22. Randomized trial of conversion from mycophenolate mofetil to azathioprine 6 months after renal allograft transplantation.
Wüthrich RP; Cicvara S; Ambühl PM; Binswanger U
Nephrol Dial Transplant; 2000 Aug; 15(8):1228-31. PubMed ID: 10910450
[TBL] [Abstract][Full Text] [Related]
23. Mycophenolate mofetil versus azathioprine for prevention of chronic allograft dysfunction in renal transplantation: the MYSS follow-up randomized, controlled clinical trial.
Remuzzi G; Cravedi P; Costantini M; Lesti M; Ganeva M; Gherardi G; Ene-Iordache B; Gotti E; Donati D; Salvadori M; Sandrini S; Segoloni G; Federico S; Rigotti P; Sparacino V; Ruggenenti P
J Am Soc Nephrol; 2007 Jun; 18(6):1973-85. PubMed ID: 17460145
[TBL] [Abstract][Full Text] [Related]
24. The effect of maintenance immunosuppression medication on the change in kidney allograft function.
Gill JS; Tonelli M; Mix CH; Johnson N; Pereira BJ
Kidney Int; 2004 Feb; 65(2):692-9. PubMed ID: 14717943
[TBL] [Abstract][Full Text] [Related]
25. Randomized, prospective trial of mycophenolate mofetil versus azathioprine for prevention of acute renal allograft rejection after simultaneous kidney-pancreas transplantation.
Merion RM; Henry ML; Melzer JS; Sollinger HW; Sutherland DE; Taylor RJ
Transplantation; 2000 Jul; 70(1):105-11. PubMed ID: 10919583
[TBL] [Abstract][Full Text] [Related]
26. Maintenance immunosuppression with mycophenolate mofetil and corticosteroids in pediatric kidney transplantation: temporary benefit but not without risk.
Cransberg K; Cornelissen M; Lilien M; Van Hoeck K; Davin JC; Nauta J
Transplantation; 2007 Apr; 83(8):1041-7. PubMed ID: 17452893
[TBL] [Abstract][Full Text] [Related]
27. Comparison of long-term actual renal allograft survival in mycophenolate mofetil and azathioprine-based triple drug immunosuppression protocols.
Attallah N; Goggins M; Nori U; Abouljoud M; Zasuwa G; Venkat KK; Parasuraman R
Transplant Proc; 2005 Jun; 37(5):2060-2. PubMed ID: 15964338
[TBL] [Abstract][Full Text] [Related]
28. Mycophenolate mofetil substitution for cyclosporine a in renal transplant recipients with chronic progressive allograft dysfunction: the "creeping creatinine" study.
Dudley C; Pohanka E; Riad H; Dedochova J; Wijngaard P; Sutter C; Silva HT;
Transplantation; 2005 Feb; 79(4):466-75. PubMed ID: 15729174
[TBL] [Abstract][Full Text] [Related]
29. Conversion from mycophenolate mofetil to azathioprine in high-risk renal allograft recipients on cyclosporine-based immunosuppression.
Lou HX; Vathsala A
Transplant Proc; 2004 Sep; 36(7):2090-1. PubMed ID: 15518756
[TBL] [Abstract][Full Text] [Related]
30. Long-term graft outcome in patients with chronic allograft dysfunction after immunosuppression modifications.
El-Agroudy AE; El-Dahshan K; Mahmoud K; El-Baz M; Shokeir AA; Ghoneim MA
Ann Transplant; 2008; 13(4):46-54. PubMed ID: 19034223
[TBL] [Abstract][Full Text] [Related]
31. Low-dose mycophenolate mofetil is an effective and safe treatment to permit phased reduction in calcineurin inhibitors in chronic allograft nephropathy.
Afzali B; Shah S; Chowdhury P; O'sullivan H; Taylor J; Goldsmith D
Transplantation; 2005 Feb; 79(3):304-9. PubMed ID: 15699760
[TBL] [Abstract][Full Text] [Related]
32. Kidney transplantation with sirolimus and mycophenolate mofetil-based immunosuppression: 5-year results of a randomized prospective trial compared to calcineurin inhibitor drugs.
Flechner SM; Goldfarb D; Solez K; Modlin CS; Mastroianni B; Savas K; Babineau D; Kurian S; Salomon D; Novick AC; Cook DJ
Transplantation; 2007 Apr; 83(7):883-92. PubMed ID: 17460558
[TBL] [Abstract][Full Text] [Related]
33. Cyclosporine withdrawal from a mycophenolate mofetil-containing immunosuppressive regimen: results of a five-year, prospective, randomized study.
Abramowicz D; Del Carmen Rial M; Vitko S; del Castillo D; Manas D; Lao M; Gafner N; Wijngaard P;
J Am Soc Nephrol; 2005 Jul; 16(7):2234-40. PubMed ID: 15917338
[TBL] [Abstract][Full Text] [Related]
34. Conversion of liver transplant recipients on cyclosporine with renal impairment to mycophenolate mofetil.
Herrero JI; Quiroga J; Sangro B; Girala M; Gómez-Manero N; Pardo F; Alvárez-Cienfuegos J; Prieto J
Liver Transpl Surg; 1999 Sep; 5(5):414-20. PubMed ID: 10477843
[TBL] [Abstract][Full Text] [Related]
35. Introduction of mycophenolate mofetil and cyclosporin reduction in children with chronic transplant nephropathy.
David-Neto E; Araujo LM; Lemos FC; David DS; Mazzucchi E; Nahas WC; Arap S; Ianhez LE
Pediatr Transplant; 2001 Aug; 5(4):302-9. PubMed ID: 11472611
[TBL] [Abstract][Full Text] [Related]
36. Tacrolimus in pancreas transplantation: a multicenter analysis. Tacrolimus Pancreas Transplant Study Group.
Gruessner RW
Clin Transplant; 1997 Aug; 11(4):299-312. PubMed ID: 9267719
[TBL] [Abstract][Full Text] [Related]
37. Predictive factors of acute rejection after early cyclosporine withdrawal in renal transplant recipients who receive mycophenolate mofetil: results from a prospective, randomized trial.
Hazzan M; Labalette M; Copin MC; Glowacki F; Provôt F; Pruv FR; Noël C
J Am Soc Nephrol; 2005 Aug; 16(8):2509-16. PubMed ID: 15987748
[TBL] [Abstract][Full Text] [Related]
38. The impact of sirolimus, mycophenolate mofetil, cyclosporine, azathioprine, and steroids on wound healing in 513 kidney-transplant recipients.
Flechner SM; Zhou L; Derweesh I; Mastroianni B; Savas K; Goldfarb D; Modlin CS; Krishnamurthi V; Novick A
Transplantation; 2003 Dec; 76(12):1729-34. PubMed ID: 14688524
[TBL] [Abstract][Full Text] [Related]
39. Chronic allograft nephropathy: a prospective randomised trial of cyclosporin reduction with or without mycophenolate mofetil.
Jain S; Metcalfe M; White SA; Furness PN; Nicholson ML
Transplant Proc; 2001 May; 33(3):2165-6. PubMed ID: 11377488
[No Abstract] [Full Text] [Related]
40. Effects of mycophenolate mofetil on donor-specific antibody formation in renal transplantation.
Lederer SR; Friedrich N; Banas B; Welser G; Albert ED; Sitter T
Clin Transplant; 2005 Apr; 19(2):168-74. PubMed ID: 15740551
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
